spacer
home > pmps > winter 2018 > demonstrating bioequivalence
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Demonstrating Bioequivalence

The global generic drugs market has experienced rapid growth in recent years, driving the need to address the specific scientific challenges facing the development of generic drug products. The demand for safe, cost-effective, and effectual treatments of respiratory diseases is also growing due to the rising global prevalence of conditions such as chronic obstructive pulmonary disease and asthma.

The development of generics requires the demonstration of bioequivalence (BE) with a reference product. BE studies typically follow on from the characterisation of a reference product and the design of a pharmaceutically equivalent and bioequivalent product. Demonstrating BE in locally-acting drugs, such as orally inhaled products (OIPs), is particularly challenging, primarily because OIP behaviour is a function of the interactions between the patient, device, and formulation. Advances in bioequivalence methodology provide an opportunity to accelerate the development and marketing of generic drugs while also maintaining safety, quality, and efficacy standards.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mark Copley graduated from the University of Bath, UK, in 2000 with a master’s degree in aerospace engineering. For eight years, he was Technical Sales Manager and Product Specialist for Copley Scientific’s range of inhaler testing equipment and is now the director of the company. Mark is considered a leading authority in testing methods and systems for metered-dose inhalers, dry powder inhalers, nebulisers, and nasal sprays – authoring and contributing to more than 40 published articles. He also provides application support and consultancy, runs focused training workshops for the inhaled drug testing sector of the pharma industry, and sits on the editorial advisory panel of Inhalation Magazine. An invited member of the European Pharmaceutical Aerosol Group impactor sub-team, Mark has also made recommendations to the Inhalanda working group, leading to subsequent revisions to Ph Eur and USP monographs.

Anna Sipitanou received a BSc in chemistry from the University of Bradford, UK, in 2014, and an MSc in drug discovery and pharmaceutical sciences from the University of Nottingham, UK, in 2015. She also undertook the role of Research Associate at Nottingham, working to build in silico models for the prediction of drug-induced liver injury. Building on her previous experience at Cellomatics Biosciences, Anna joined Copley Scientific in July 2017 as Business Development Manager, playing a key role in the company’s service to customers, including training of a wide range of instruments.
spacer
Mark Copley
spacer
spacer
spacer
Anna Sipitanou
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cheshire Business Awards 2018: Technoprint Cheshire Ltd. wins Corporate Social Responsibility Award

Technoprint has prided itself on being a socially responsible organisation since it was founded in 1988. Winning the Corporate Social Responsibility award is a real testament to their ethos and shows that hard work and making a difference to the local area really does make an impact in the long term, internally and externally.
More info >>

White Papers

How To Increase Efficiency, Customer Satisfaction and Reduce Cost

AC Labels

A customer of Riverside Medical had required a complex four-part 'piggy back' label. The labels needed to be specially constructed to facilitate removal in parts at various stages of its use for quality control traceability. This label needed to carry variable data elements of LOT numbers, batch numbers and product descriptions, and also a secondary gamma indicator label placed on each of its 4 sections to prove its sterility following sterilisation.
More info >>

 
Industry Events

Drug Delivery Partnerships 2019

28-30 January 2019, PGA National Resort & Spa in Palm Beach Gardens, FL

For 23 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies. Year after year this event brings together top scientists and business development leaders from Biotech, Pharma, Generics, Specialty Pharma and Drug Delivery companies to share, discuss, and collaborate. If you work in drug delivery, commercialization/licensing, med device, formulation, biologics, biosimilars, and similar areas, you can’t miss this event!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement